Bpifrance SA - Q4 2021 holdings

$4.21 Billion is the total value of Bpifrance SA's 9 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 12.5% .

 Value Shares↓ Weighting
STLA  STELLANTIS NV$3,640,081,000
-1.6%
192,703,9070.0%86.37%
+1.8%
CSTM  CONSTELLIUM NVcl a$293,615,000
-4.6%
16,393,9030.0%6.97%
-1.4%
FTI SellTECHNIPFMC PLC$122,454,000
-34.6%
20,656,724
-16.3%
2.91%
-32.4%
CRTO  CRITEO S Aspons ads$105,678,000
+6.1%
2,718,7520.0%2.51%
+9.7%
SQNS  SEQUANS COMMUNICATIONS S Aspons ads$15,642,000
+8.0%
3,300,0180.0%0.37%
+11.7%
VECT  VECTIVBIO HOLDING AG$13,779,000
-36.4%
2,806,2170.0%0.33%
-34.2%
NewMIRION TECHNOLOGIES INC$13,469,0001,286,446
+100.0%
0.32%
VCYT SellVERACYTE INTERNATIONAL$6,273,000
-73.1%
152,261
-69.7%
0.15%
-72.1%
CLLS  CELLECTISspons ads$3,457,000
-35.6%
425,7260.0%0.08%
-33.3%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-02-11
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
CRITEO S A20Q3 202310.1%
TECHNIPFMC PLC13Q4 202168.1%
STELLANTIS NV11Q3 202390.9%
CONSTELLIUM NV11Q2 202141.6%
SEQUANS COMMUNICATIONS S A11Q2 20215.8%
CELLECTIS S.A.10Q2 20232.3%
CONSTELLIUM NV9Q3 20238.3%
SEQUANSCOMMUNICATIONS S A9Q3 20230.5%
MILLENDO THERAPEUTICS INC8Q3 20201.8%
VECTIVBIO HOLDING AG8Q1 20230.8%

View Bpifrance SA's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-07
13F-HR2023-11-13
13F-HR2023-07-28
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-11
13F-HR2022-05-16
13F-HR2022-02-11
13F-HR2021-11-15

View Bpifrance SA's complete filings history.

Compare quarters

Export Bpifrance SA's holdings